Streetwise Expert Interviews

William Plovanic

Medtech Shifts from High Gear into Overdrive: Canaccordís William Plovanic

Rapid growth in the medical device industry and changes in the regulatory environment have propelled valuations in the medtech sector to the high end of the range. But new technologies create new investment opportunities. In this interview with The Life Sciences Report, William Plovanic of Canaccord Genuity highlights investment opportunities in medtech companies with innovative products targeting high-impact areas such as obesity, diabetes and wound care. (8/19/14) More >

Wedbush Securities' Liana Moussatos on the Art and Science of Picking Biotechs with Upside

pillsben82Liana Moussatos of Wedbush Securities doesn't wait for the catalyst to strike. She, like other successful investors, picks her targets and takes profits earlier, while less sophisticated investors wait for the press releases. In this interview with The Life Sciences Report, Moussatos describes a group of biotech stocks rich with upcoming catalysts, and invites investors to sample what she expects will be exceptional profits. (8/18/14) More >

Jim Collins

Jim Collins: Five Names to Love from the LD Micro Conference

The conference circuit can be a brutal one, with scores of companies vying for investor attention, but some vendor halls hold more opportunities than others. In this interview with Streetwise Reports' Special Situations, Jim Collins, author of The Portfolio Guru, shares his finds from the productive LD Micro Conference, an event he describes as a "micro-cap love-in." He details a quintet of investing opportunities, from areas as varied as deep-sea exploration support services, Wi-Fi energy delivery and drinks for kids. (8/20/14) More >

Read more Streetwise interviews. . .

including Bring On the Orphans: Aegis Capital's Raghuram Selvaraju Lays Out a Winning Biotech Strategy (8/14/14) More >

Newsletter Briefs

"There's more to OMER than Omidria; the company has quite a pipeline." (8/21/14) Omeros Corp. - The Life Sciences Report interview with Liana Moussatos More†>

"MDXG provides better, faster and cheaper technology compared to current wound-care therapies." (8/19/14) MiMedx Group Inc. - William Plovanic, Canaccord Genuity More†>

"CUR has two very credible shots on goal." (8/13/14) Neuralstem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More†>

"ARNI's onapristone could potentially be a suprabillion-dollar drug upon approval." (8/13/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More†>

"RP is at the forefront of the utilization of stem cells to treat disorders and defects." (8/7/14) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Mark Landy More†>

"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More†>

"A rapid and economical test like AMBS' LymPro could be used to improve Alzheimer's patient enrollment for future clinical trials." (8/6/14) Amarantus BioScience Holdings Inc. - Jason Napodano, Seeking Alpha More†>

"We are very excited about RNN; it's an early-stage oncology company with multiple shots on goal." (7/31/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Christopher James More†>

Expert Analysis

"DMPI announced FDA approval for an expanded dosing regimen in a Phase 1/2 trial evaluating VAL-083 in glioblastoma multiforme patients." (8/21/14) DelMar Pharmaceuticals Inc. - Jerry Isaacson, LifeSci Advisors More†>

"IMNP will begin trading on the NASDAQ; the uplisting should improve the liquidity and marketability of shares." (8/20/14) Immune Pharmaceuticals Inc. - Jerry Isaacson, LifeSci Advisors More†>

"Commercial launch of AMBS' LymPro remains on track for H2/14." (8/18/14) Amarantus BioScience Holdings Inc. - Mick Cooper, Edison Investment Research More†>

"RXII could report preliminary data over the next four to six months." (8/15/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More†>

"NEO bolstered its balance sheet with ~$30M via a secondary offering." (8/15/14) NeoGenomics Laboratories - Debjit Chattopadhyay, ROTH Capital Partners More†>

"The RNN story can now be viewed as a ground floor opportunity." (8/14/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More†>

"CGIX has sufficient capital to fund operations to break even status." (8/14/14) Cancer Genetics Inc. - Ram Selvaraju, Aegis Capital More†>

"STEM's Q2/14E cash is enough to reach its AMD trials' proof of concept." (8/13/14) StemCells Inc. - Jason Kolbert, Maxim Group More†>